BrainsWay Ltd. (NASDAQ:BWAY) Sees Large Increase in Short Interest

BrainsWay Ltd. (NASDAQ:BWAY) was the target of a large growth in short interest in April. As of April 15th, there was short interest totalling 79,800 shares, a growth of 6.7% from the March 31st total of 74,800 shares. Based on an average trading volume of 108,100 shares, the days-to-cover ratio is currently 0.7 days.

BrainsWay Stock Performance

Shares of BrainsWay stock opened at $5.56 on Thursday. BrainsWay has a twelve month low of $1.38 and a twelve month high of $7.61. The company’s 50 day moving average is $5.60 and its 200 day moving average is $5.61.

BrainsWay (NASDAQ:BWAY) last released its quarterly earnings results on Wednesday, March 6th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.02. BrainsWay had a negative return on equity of 10.05% and a negative net margin of 13.20%. The firm had revenue of $9.03 million for the quarter, compared to analysts’ expectations of $8.40 million. During the same period in the prior year, the firm earned ($0.12) EPS. Equities analysts expect that BrainsWay will post -0.02 EPS for the current fiscal year.

Institutional Investors Weigh In On BrainsWay

Large investors have recently made changes to their positions in the company. Acadian Asset Management LLC bought a new position in shares of BrainsWay in the 3rd quarter worth approximately $28,000. Tucker Asset Management LLC raised its position in BrainsWay by 1,686.9% in the fourth quarter. Tucker Asset Management LLC now owns 5,450 shares of the company’s stock worth $35,000 after acquiring an additional 5,145 shares during the period. Quadrature Capital Ltd purchased a new position in shares of BrainsWay during the 4th quarter worth $70,000. Jump Financial LLC bought a new stake in shares of BrainsWay during the 4th quarter valued at $207,000. Finally, Legato Capital Management LLC bought a new stake in shares of BrainsWay during the 4th quarter valued at $542,000. 30.11% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating on shares of BrainsWay in a report on Monday, March 11th.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.